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Abstract
Background
Prior studies have shown that switching patients from inducing antiepileptic 
drugs (AEDs) to lamotrigine, levetiracetam, or topiramate reduces serum 
lipids and C-reactive protein (CRP). These studies were all of short duration, 
and some drugs, such as zonisamide, have not been investigated.  
Methods 
We recruited 41 patients taking phenytoin or carbamazepine who were being
switched to zonisamide, lamotrigine, or levetiracetam. We measured serum 
lipids and CRP before the switch, >6 weeks after, and >6 months after. An 
untreated control group (n=14) underwent similar measurement. We 
combined these data with those of our previous investigation (n=34 patients 
and 16 controls) of a very similar design.  
Results 
There were no differences in outcome measures between the two inducing 
AEDs, nor among the three non-inducing AEDs. Total cholesterol (TC), 
atherogenic lipids, and CRP were higher under inducer treatment than in 
controls. All measures were elevated under inducer treatment relative to 
non-inducer treatment, including TC (24 mg/dL higher, 95% CI: 17.5-29.9, 
p<0.001) and CRP (72% higher, 95% CI: 41-111%, p<0.001). The difference 
between drug treatments was clinically meaningful for atherogenic lipids 
(16%, 95% CI: 11-20%, p<0.001) but small for high-density-lipoprotein 
cholesterol (5%, 95% CI: 1-9%, p<0.05). All measures were stable between 6
weeks and 6 months after drug switch.
Conclusions 
We demontrate that switching from inducing to non-inducing AEDs produces 
an enduring reduction in serum lipids and CRP. These results provide further 
evidence that inducing AEDs may be associated with elevated vascular 
disease risk. These are the first vascular risk marker data in patients taking 
zonisamide, which shows a profile similar to that of other non-inducing AEDs.
Introduction
Many studies have demonstrated that use of antiepileptic drugs (AEDs) 
which induce the cytochrome P450 (CYP450) system is associated with 
higher serum lipid levels and elevated C-reactive protein (CRP). This has 
been shown in cross-sectional studies1,2 and in repeated-measures analyses3.
Most compelling are studies directly demonstrating that switching patients 
from carbamazepine (CBZ) or phenytoin (PHT) to non-inducing AEDs results 
in significant reductions in these vascular risk markers. To date, reduction in 
total cholesterol has been documented upon switch from these inducing 
agents to lamotrigine (LTG), levetiracetam (LEV), oxcarbazepine, or 
topiramate4-6. However, all of these studies have been short in duration, with 
lipids assessed 6-8 weeks after the change in medication. Without longer-
term studies, there is no way to ascertain whether this is a transient change 
which will be undone by homeostatic mechanisms, or a permanent change 
from withdrawal of the inducing AED. In fact, there are reports that some 
AED-induced lipid changes are transient in nature7,8.
Thus, our goal was to determine whether improvements in lipids and 
CRP due to changes in AED therapy are enduring. We utilized a repeated-
measures design, so that each patient could effectively serve as his or her 
own control. In addition, we extend our findings here to include the non-
inducing AED zonisamide (ZNS), an agent for which there are no data with 
respect to lipids to date, to our knowledge.
Methods
Our study population consisted of a group of adult patients with focal 
epilepsy (age 18 years or older) who were being treated in monotherapy with
either PHT or CBZ, and who were being crossed over to monotherapy with 
one of three newer-generation non-inducing AEDs: ZNS, LTG, or LEV. The 
large majority of these patients had focal epilepsy. Patients taking a lipid-
lowering agent were excluded from the study to avoid having drug 
interactions confound the results. A group of normal subjects, also age 18 
years or older, without epilepsy and not taking any AED or any lipid-lowering 
agent, served as controls; this was a convenience sample of people available
to the investigators and all were newly-recruited for the present 
investigation.
The decision to switch AEDs was made on clinical grounds by the 
managing physician at the Jefferson Comprehensive Epilepsy Center and was
not, itself, part of the study; patients may have been switched due to side 
effects from their existing AED, continued seizures, pregnancy planning, or 
concern about potential long-term AED effects, but in all cases this plan was 
undertaken by the managing physician for the patient’s benefit. Only once 
that therapeutic plan was made was the patient was asked to consent to 
participate in the study so that serologic data could be provided while the 
drug switch was being pursued. The rate of initiation of therapy with the new
agent and taper of the old agent was at the discretion of the treating 
physician and was individualized for each patient. The minimum target dose 
for the new AED was 200 mg daily for LTG or ZNS, and 1000 mg daily for LEV.
The design of the study entailed each drug-treated patient having blood 
drawn after a minimum of 10 hours fasting on 3 occasions: first at baseline, 
while still taking the old AED; a second time early after switching, at least 6 
weeks after the last dose of the older AED was taken; and a third time long 
after switching, at least 4.5 months after the second draw (constituting at 
least 6 months after the medication crossover was completed). Likewise, 
control subjects were to have fasting blood samples drawn at baseline, 10 
weeks later (to simulate the time that would be required for cross-titration of 
medication), and 6 months after baseline. Samples were analyzed for serum 
lipids, including lipid fractions, and CRP.
The design and population for this study were very similar to those of 
our previous investigation, in which patients taking CBZ or PHT were crossed 
over to either LTG or LEV; however, in that study, patients had blood drawn 
only twice: before the switch, while taking the EIAED, and a second time at 
least 6 weeks after switch to the newer drug. In 11 of those patients, we 
were able to obtain a third blood sample, at least 4.5 months after the 
second one, to mirror the design of the present study; this represents 
additional data which was not available at the time of the original report. 
Because of the similarities in design and population, data from the remainder
of the prior cohort, who had had only two blood draws, were included in the 
present analysis in order to maximize the amount of data on each individual 
AED for the statistical model. A few patients from the newly-recruited cohort 
were lost to follow-up and also provided only 2 blood samples; their data was
included as well, for the same reason. Analogously, a cohort of controls who 
provided 3 serologic samples was recruited for the present study, and 
combined with the control group from the prior study, who provided 2 blood 
samples. Two participant patients, one taking LTG and one taking LEV, had 
their AED changed owing to significant side effects after providing the 
second blood sample; both were switched to ZNS at the discretion of the 
treating physician, and they remained in the study, providing a third blood 
sample that was analyzed as having been obtained under ZNS treatment. 
(We considered this “per protocol” analysis, rather than an intention-to-treat 
analysis, to be most appropriate because the study outcome measures are 
objective and thus unbiased.) Serology was performed by a specialty lipid 
laboratory (Liposcience, Raleigh NC) according to the specifications 
documented in our previous report5.
For statistical analysis, the repeated measures Total Cholesterol (TC) and
log transformed measures of CRP, high-density lipoprotein cholesterol (HDL-
C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TRIG), and non-
HDL cholesterol (TC minus HDL-C) were analyzed in separate linear mixed 
effects models adjusting for correlation among repeated draws per patient. 
After log transformations, and excluding one LDL observation as potential 
outlier, the normal distribution assumption was valid as determined by 
examination of the residuals and estimates of the patient random effects. 
The initial models included the following covariates (predictors): drug group 
(OLD=(CBZ or PHT), NEW=(LEV, LTG, ZNS) or NONE), draw (1, 2, or 3) and 
gender. The difference between draws was not significant in any of the 
models and was not included in the final models. Gender was retained in the 
final models if it was a significant predictor. Data were analyzed in SAS 9.1 
(SAS Institute Inc., Cary, NC, USA) and S-Plus (Insightful Corporation, Seattle,
Washington). This study was approved by the Institutional Review Board of 
Thomas Jefferson University.
Results
Our analysis included a total of 75 drug-treated epilepsy patients (33 
female), with a mean age of 40 (±14) years. This included 41 newly-recruited
for this study, all but 3 of whom provided all 3 serologic samples. An 
additional 34 patients from the prior study were also included in the analysis,
of whom 11 provided a third blood sample. Thus, there were 49 patients who
provided all 3 samples, and 26 who provided just the first 2 (pre-switch, and 
>6 weeks after switch). The control group consisted of 30 subjects (18 
female), with a mean age of 35 (±13) years, of whom 14 provided 3 blood 
samples, and 16 provided the first two. The mean time between the first two 
serologic tests was 113 (± 51) days in the patients and 80 (± 33) days in the
controls; this accounts for both the time taken to taper the original AED and 
the waiting period of at least 6 weeks after it was stopped (along with any 
delays in getting the patient back to the clinic for the follow-up visit). The 
mean time between the second and third samples was 250 (± 71) days in 
the drug-treated patients and 257 (± 31) days in the controls, again 
accounting for both the AED taper and the waiting period of at least 6 
months after it was stopped. Neither age nor gender differed significantly 
between the patient and control groups, and age did not impact upon any of 
the outcome measures. Gender did have an impact on some of the lipid 
measures, however, and this was accounted for in the statistical models 
when appropriate.
Analysis demonstrated that there was no difference in any outcome 
measure between the individual inducing AEDs (PHT and CBZ), nor between 
the individual non-inducing AEDs (LEV, LTG, and ZNS). Furthermore, the 
sequence of blood draws (1, 2, or 3) had no association with the outcome 
measures once the drug was taken into account. Thus, the final statistical 
model combined all samples taken during inducing AED treatment in one 
common group, all samples taken during non-inducing AED treatment as a 
second common group, and all samples taken from the untreated controls in 
a third common group. These data are presented in the Table. All lipid 
measures and CRP were significantly higher during inducing AED treatment 
than during non-inducing AED treatment. Specifically, TC was higher on 
average by 24 mg/dL (95% CI: 18-30; p<0.001), non-HDL-C was higher on 
average by 16% (95% CI: 11%-20%; p<0.001), HDL-C was higher on average
by 5% (95% CI: 1%-9%; p=0.017), TRIG were higher on average by 36% 
(95% CI: 23%-50%; p<0.001), LDL-C was higher on average by 7% (95% CI: 
2%-12%; p=0.010), and CRP was higher on average by 72% (95% CI: 41%-
111%; p<0.001). These differences are reported in percentage terms (except
for TC) because the data underwent log transformation for statistical 
analysis. TC was also elevated in patients during inducing AED treatment 
relative to untreated controls (mean difference=18mg/dL, 95% CI: 4-33; 
p=0.015), as were non-HDL-C (mean difference=13%, 95% CI: 1%-25%; 
p=0.030) and CRP (mean difference=141%, 95% CI: 39%-319%; p=0.002). 
There were no differences between the values obtained in patients during 
non-inducing AED treatment and those seen in controls except for TRIG, 
which was lower in the former (by an average of 23%, 95% CI: 3%-38%, 
p<0.05).
Figure 1 shows the change in TC, LDL-C, TRIG, and CRP between draw 1 
and draw 2, subdivided by both the drug the patient was initially taking and 
the drug to which the patient was switched. Most results were fairly 
consistent, regardless of specific AED, with some variation between the 
individual drugs that is not significant. Particular uniformity was seen 
regarding changes in TRIG and CRP, while TC and LDL-C exhibited more intra-
group variability, as evidenced by the large standard deviations.
Figure 2 shows the mean values for TC, non-HDL-C, HDL-C, and CRP 
separately for each of the 3 blood draws (before switch, ≥6 weeks after 
switch, and ≥6 months after switch), subdivided by the non-inducing AED to 
which the patient was switched. Again, outcome values were consistent 
across the 3 AEDs. In addition, little change is seen in mean values between 
draw 2 and draw 3, indicating that the effects of AED switch appear to have 
taken full effect by 6 weeks after completion of the crossover.
Discussion
We show here, for the first time, that switching patients from the 
enzyme-inducing agents PHT or CBZ to non-inducing AEDs produces a 
reduction in serum cholesterol and CRP that is enduring, rather than the 
product of a temporary homeostatic reaction. While one group has reported 
changes in lipids with various AEDs have resolved after a year of therapy or 
more 8,9, this stands in contrast to many cross-sectional studies in adults and 
children (reviewed in LoPinto-Khoury and Mintzer10) in which patients under 
long-term treatment with CBZ have elevated lipid values relative to controls. 
Some of our data comes from continued observation of patients enrolled in 
our prior study, but more than half (41 of 75) were newly-recruited patients, 
and this, along with the size of the total cohort, are among the strengths of 
the present report.
This study is also, to our knowledge, the first to measure lipid levels in 
patients taking ZNS, a broad-spectrum AED which has been used in Asia and 
the United States for many years, and was more recently approved in Europe
following a large randomized trial in newly-diagnosed focal epilepsy patients 
which demonstrated very similar efficacy to CBZ11. Data now exist to verify 
that lipids and CRP will decline if patients taking inducing AEDs are switched 
to ZNS, LTG, LEV, TPM, or OXC4-6.
Our study provides further strong evidence that inducing AEDs elevate 
serum lipids and CRP. The particular value of the “drug switch” paradigm is 
that it demonstrates that changes in lipids and CRP are due to the change in 
drug treatment, rather than due to differences in patient population, as could
be the case in a cross-sectional study. In theory, this could also be due to 
some lipid-lowering effect of LEV, LTG, and ZNS. But all outcome measures 
(except TRIG) were similar between the newer AED group and the controls, 
with the older AED group higher, suggesting that it is the inducing AEDs that 
cause the derangement. The cross-sectional studies mentioned above also 
point to the former hypothesis. Furthermore, there is clinical and 
pharmacologic reasoning to apply. The second hypothesis implies that LEV, 
LTG, ZNS, topiramate, and oxcarbazepine, 5 drugs which are wholly 
dissimilar in their chemical structure and pharmacologic action, have in 
common some property which leads to a comparable reduction in lipids. 
Thus, whatever property is responsible for changes in lipids after AED switch 
must differ between PHT and CBZ on the one hand, and LTG, LEV, ZNS, 
oxcarbazepine, and topiramate on the other. Induction of the CYP450 system 
is by far the most likely culprit, particularly in view of the involvement of 
CYP450 enzymes in the cholesterol synthetic pathway12. Oxcarbazepine and 
topiramate are only limited (and possibly dose-dependent) inducers of 
CYP450 enzymes13-15, and LTG, LEV, and ZNS have no effect upon the P450 
system, whereas PHT and CBZ are broad and powerful inducers. 
Furthermore, there is evidence in laboratory animals that CYP450 inhibition 
leads to reduced cholesterol production12 and that patients exposed to 
valproate, a CYP450 inhibitor, have lower cholesterol levels2,16. Thus, the sum
total of evidence strongly implies that PHT and CBZ elevate lipids and CRP 
because of their enzyme-inducing capacity, and that the changes are 
enduring, clinically significant, and reversible.
In this study, differences between the groups in LDL-C were modest. This
is the case despite the fact that both TC and non-HDL-C (the total of 
atherogenic lipid components, calculated as TC minus HDL-C), are 
significantly elevated by the use of inducing AEDs. Non-HDL-C is mainly 
comprised of VLDL-C and LDL-C. It appears that enzyme induction from AEDs
results in variable increases in subfractions of atherogenic lipids, with more 
accruing in the VLDL-C fraction than the LDL-C fraction. VLDL are the 
predominant carriers of TRIG, so the large difference seen in TRIG values 
between inducing and non-inducing AED use corroborates this. One odd 
finding of our study is that TRIG values in controls were similar to those seen 
with inducing AED treatment, and lower than those seen with non-inducing 
AED treatment. This is incongruous with the rest of the data, and there is no 
obvious explanation; it may be a statistical fluke, but this should be 
examined in future studies. Our study also confirmed that inducing AEDs, 
while they increase atherogenic lipids, also increase the beneficial HDL-C, 
though apparently too modestly (2-3 mg/dL) to have much clinical impact on 
cardiovascular disease incidence.
Our study has verified that CRP declines prominently and in an enduring 
fashion when patients are switched from inducing to non-inducing AEDs. 
Since drugs which lower cholesterol also lower CRP, it is possible that this is 
an epiphenomenon. Alternatively, it is possible that inducing AEDs also 
produce alterations in the inflammatory pathways, of which CRP is the most 
commonly-measured marker. Further studies should examine whether other 
markers of inflammation are likewise affected by AED treatment.
A limitation of the study is that we did not account for other factors that 
could influence the primary outcome markers, such as body weight, diet, 
exercise, or smoking. However, since each patient serves as his or her own 
control, inter-subject differences would be very unlikely to have an impact on
the results; there would have to be changes in these factors within patients 
over the course of the study, and it is highly doubtful that any such changes 
would account for our findings. Another limitation is that we did not measure 
other markers associated with vascular disease, such as apolipoprotein levels
or homocysteine; whether or not these markers contribute meaningfully to 
vascular risk stratification beyond the more established markers is the 
subject of much debate within the cardiovascular community.
Studies in the literature demonstrate that the relative risk of a major 
vascular event changes by roughly 1% for each change in TC of 1 mg/dL (see
supplementary material in Mintzer et al 5). Thus, based simply on the change
in TC, one of the oldest and most established surrogate markers in medicine, 
we would expect that exposure to an inducing AED should raise the risk of 
vascular disease by approximately 25%. Thus is mitigiated only very slightly 
-- around 5% -- by the small concomitant elevation in HDL-C. Once the 
change in CRP -- an independent risk factor -- is factored in, we would expect
the increase in relative vascular risk with inducing AED treatment to be 
around 33%, which is clinically meaningful by anyone’s standards, 
particularly given the enormous number of patients worldwide who are 
treated with these agents both for neurological and psychiatric purposes.
Both CBZ and PHT remain commonly-used treatment options throughout
the world, but mounting evidence demonstrates that newer drugs are 
equally effective for focal epilepsy 11,17-20. We now have good evidence to 
demonstrate that each of these non-inducing drugs avoids the elevation of 
vascular risk markers — and possible promotion of atherosclerosis1 — which 
occurs with the inducing AEDs. CBZ and PHT are also responsible for a 
plethora of other metabolic derangements, including alteration of vitamin 
levels5,21 bone metabolism22,23, male reproductive function24, and many drug 
interactions25. In view of these findings, there is increasing reason to believe 
that the use of enzyme-inducing AEDs is problematic. This is particularly true
in early-stage disease, because if patients do well, but are subsequently 
found to have metabolic side effects, there is a modest but measurable risk 
of recurrence from switch to a different AED26. Thus, choosing the right drug 
in the first place may avoid problems later.
In summary, switching patients from inducing to non-inducing AEDs 
produces long-term improvement in serologic markers of vascular risk. Since 
inducing AEDs appear to be the culprits, patients taking PHT and CBZ should 
be screened for vascular risk (via lipid and CRP studies, and possibly stress 
tests or other measures). Patients taking phenobarbital or primidone, both of 
which are also potent inducers of the CYP450 system, may be at risk too and 
should likely be screened for hyperlipidemia and other metabolic 
derangements10. If non-HDL-C or CRP are elevated they may be treated, but 
many lipid- lowering agents are themselves induced by the CYP450 system, 
so higher doses may be needed. Alternatively, the patient may be switched 
to any of several non-inducing AEDs to reverse the problem for the long-
term. We have here demonstrated the benefit of doing so, though if the 
patient is seizure-free this must be weighed against the modest but 
meaningful chance of recurrence with AED switch26. 
Table
Table. Mean values (with 95% confidence intervals) of lipid measures and C-
reactive protein (CRP) in patients during treatment with an inducing AED, in 
the same patients during treatment with a non-inducing AED, and in controls 
treated with no AED. For inducing AED-treated patients, values from samples 
2 and 3 averaged together. For controls, values from all samples averaged 
together. All measures in mg/dL, except CRP in mg/L. HDL = high-density 
lipoprotein. LDL = low-density lipoprotein.
Group →
Measure↓ Inducing AED Non-inducing AED No AED p-values
Total
cholesterol
213.0
(204.6 - 221.5)
189.3
(181.3 - 197.3)
194.7
(182.7 - 206.8)
<0.001*
<0.05†
non-HDL
cholesterol
146.3
(137.8 - 155.3)
126.4
(119.3 - 133.8)
130.0 
(119.1 - 141.9)
<0.001*
<0.05†
LDL
cholesterol
116.4
(108.9 - 124.4)
109.3 
(102.6 - 116.4)
113.5
(103.2 - 124.8)
<0.02*
HDL
cholesterol
59.2
(55.9 -  62.6)
56.5
(53.5 - 59.6)
57.7
(53.2 - 62.7)
<0.02*
Triglycerides 100.3
(87.4 - 115.1)
73.7
(65.1 - 83.4)
95.3
(79.1 - 114.9)
<0.001*
<0.05§
CRP 3.1
(2.2 - 4.2)
1.8
(1.3 - 2.4)
1.3
(0.8 - 2.0)
<0.001*
<0.01 †
*For difference between inducing and non-inducing AED
†For difference between inducing AED and no AED
‡p<0.01 for difference between inducing AED and no AED
§For difference between non-inducing AED and no AED
Figure Legends
Figure 1A-D. Change in outcome measures between the first and second blood samples,
subdivided by the drug the patient was originally taking (phenytoin[PHT] or 
carbamazepine[CBZ]) and the drug to which the patient was switched (lamotrigine[LTG], 
levetiracetam[LEV], or zonisamide[ZNS]). Data shown are means and 95% confidence 
intervals for total cholesterol (A), low-density lipoprotein cholesterol (B), triglycerides (C), 
and C-reactive protein (D). For LEV, n=8 patients originally taking CBZ and n=20 originally 
taking PHT. For LTG, n=19 switched from CBZ and n=11 switched from PHT. For ZNS, n=9 
patients switched from CBZ and n=8 switched from PHT.
Figure 2A-D. Outcome measures for each of the three serologic samples, subdivided by 
the drug to which the patient was switched (lamotrigine[LTG], levetiracetam[LEV], or 
zonisamide[ZNS]). Data shown are means and 95% confidence intervals for total cholesterol 
(A), high-density lipoprotein cholesterol (B), non-high-density lipoprotein cholesterol (C), and 
C-reactive protein (D). For the LEV patients, n=28 for the first and second sample times and 
n=11 for the third. For LTG patients, n=30 for the first two samples and n=19 for the third. 
For ZNS patients, n=17 for the first two and n=16 for the third.
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